CAR-T CDMOs — Ranked by Signal Score · 2026
39
CDMOs tracked
31
Fully scored
7
With FDA records
36
FDA inspections
123
EMA/MHRA GMP certs
On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg), Novartis, and City of Hope (T Cell Manufacturing) lead the CAR-T CDMO rankings. Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. CAR-T CDMO selection turns on vector supply (in-house vs sourced), autologous logistics maturity, closed-system processing at parallel scale, and regulatory posture. Rankings are recomputed daily. Full methodology at cdmosignal.com/methodology.
CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.
Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 17 NAI (no action), 17 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Austria (42), United States (31), Denmark (18), Germany (12), France (8).
Last updated 2026-08-18. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
BMS
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
|
90.8 | 97.0 | 6 insp · 2 GMP | — | 583 programs |
| 2 |
Novartis
Basel, Switzerland
|
88.3 | 90.9 | 15 insp · 62 GMP | — | 135 programs |
| 3 |
COH
City of Hope (T Cell Manufacturing)
Duarte, CA
|
83.8 | 96.8 | 3 insp · 0 GMP | — | 211 programs |
| 4 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 5 |
NV
Novartis Contract Manufacturing
Morris Plains, NJ · Stein, CH
|
79.1 | 90.9 | — | Constrained | 284 programs |
| 6 |
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
|
74.6 | 100.0 | 0 insp · 2 GMP | — | 8 programs |
| 7 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 8 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
83.7 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 9 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.5 | 100.0 | 1 insp · 6 GMP | Limited | 0 programs |
| 10 |
SC
SCTbio
Prague, Czech Republic
|
81.6 | 100.0 | 0 insp · 5 GMP | — | 0 programs |
| 11 |
CF
CELLforCURE (SEQENS)
Les Ulis, FR
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 12 |
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
|
80.2 | 98.8 | 1 insp · 1 GMP | Available | 0 programs |
| 13 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 14 |
GS
GenScript ProBio
Piscataway, NJ · Nanjing, CN
|
79.5 | 100.0 | — | Constrained | 0 programs |
| 15 |
OR
Ori Biotech
London, UK
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 16 |
FH
Fred Hutch Cell Therapy Lab
Seattle, WA
|
76.4 | — | — | — | 453 programs |
| 17 |
GenScript
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
|
65.5 | — | — | — | 0 programs |
| 18 |
CT
CTMC
Houston, TX
|
63.0 | — | — | — | 0 programs |
| 19 |
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
|
63.0 | — | — | — | 0 programs |
| 20 |
MX
MaxCyte
Gaithersburg, MD
|
62.0 | — | — | — | 0 programs |
| 21 |
CL
Cellares
South San Francisco, CA
|
61.5 | — | — | Available | 0 programs |
| 22 |
MS
Made Scientific
Princeton, NJ
|
61.5 | — | — | — | 0 programs |
| 23 |
Minaris (WuXi Advanced Therapies)
Philadelphia, PA / Yokohama, Japan
|
60.5 | — | — | — | 0 programs |
| 24 |
TR
Takara Bio
Kusatsu, Shiga Prefecture, Japan
|
59.5 | — | — | — | 8 programs |
| 25 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 26 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 27 |
EX
Excellos
La Rochelle, France
|
59.0 | — | — | — | 0 programs |
| 28 |
CZ
Cellex Cell Professionals
Cologne, Germany
|
59.0 | — | — | — | 0 programs |
| 29 |
AS
Artis BioSolutions
Lake Nona, FL
|
59.0 | — | — | — | 0 programs |
| 30 |
CTP
Cell Therapies Pty Ltd
Melbourne, Australia
|
59.0 | — | — | — | 0 programs |
| 31 |
PO
Poseida Therapeutics (CDMO)
San Diego, CA
|
58.7 | — | — | — | 6 programs |
| — |
Kite Pharma (Gilead Sciences)
Santa Monica, CA
|
Profiled | — | — | — | 0 programs |
| — |
Rose BioSolutions
Wilmington, MA
|
Profiled | — | — | — | 0 programs |
| — |
Cellipont Bioservices
The Woodlands, TX
|
Profiled | — | — | — | 0 programs |
| — |
Porton Advanced
Cranbury, NJ
|
Profiled | — | — | — | 0 programs |
| — |
Magellan Stem Cells
Sydney, Australia
|
Profiled | — | — | — | 0 programs |
| — |
Landmark Bio
Watertown, MA
|
Profiled | — | — | — | 0 programs |
| — |
Navigate BioPharma Services, Inc.
Carlsbad, CA
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
What to evaluate in a CAR-T CDMO
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
In-house vs sourced vector — how CAR-T CDMOs differ
CAR-T needs a lentiviral or retroviral vector to transduce patient T cells. CDMOs that produce vector in-house eliminate one supply-chain seam and shorten tech-transfer paths, but often at higher cost and narrower serotype flexibility. CDMOs that source vector externally can pair with specialized viral vector CDMOs — see the Lentiviral Vector CDMO ranking — but must coordinate two contracts and comparability datasets. Sponsors should also ask whether the CDMO's cell therapy site is on the same campus as vector production; geographic co-location reduces shipping, transfer, and validation overhead.
Which CAR-T CDMOs handle allogeneic programs?
Most CAR-T CDMO capacity today is designed around autologous per-patient batching. Allogeneic CAR-T — using donor cells expanded to master cell banks — requires different process design and typically larger batch scale. CDMO profile pages flag "cell therapy" and "car-t" modality tags; CDMOs marked with both, and with capacity signals indicating larger-batch infrastructure, are the candidates for allogeneic programs. Sponsors should specifically ask about closed-system automation designed for the target manufacturing scale (per-donor batches vs unit-per-patient).
Commercial CAR-T CDMO capabilities
Commercial CAR-T manufacturing — supporting an approved product — is currently done by a small set of CDMOs (or in-house at the innovator). The commercial-scale CAR-T filter surfaces CDMOs with top-quartile Signal Score. Commercial CAR-T requires not just cGMP capacity but validated chain-of-identity, real-time release testing infrastructure, and demonstrated vein-to-vein turnaround performance under commercial volumes. Sponsors moving from clinical to commercial should assume 12–18 months of tech transfer even with a CDMO that has commercial CAR-T experience.
How CDMO Signal computes the CAR-T ranking
The CAR-T Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications (NAI, VAI, OAI), Warning Letter history, and EMA/MHRA GMP certificate density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint matched to each CDMO — for CAR-T this pillar carries strong signal since clinical activity closely tracks real manufacturing depth. Financial Stability (20%) draws on SEC filings and parent-company signals. Capacity Intelligence (20%) tracks monitored trade press for facility expansions. Full weightings at cdmosignal.com/methodology.
CAR-T CDMOs — Frequently Asked Questions
Who are the top CAR-T CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked CAR-T CDMOs include Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many CAR-T CDMOs have FDA inspection records?
CDMO Signal tracks 7 CAR-T CDMOs with FDA inspection records and 123 EMA/MHRA GMP certificates across the group.
What should I look for in a CAR-T CDMO?
Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.
Do CAR-T CDMOs make their own viral vectors?
Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.
Related modalities